Entering text into the input field will update the search result below

8 Reasons Gilead Will Remain Golden

The market has had a good week as it bounces off the recent sell-off. It will be interesting to see if this rally can hold through the jobs report on Friday. One stock I like regardless of how the job report comes out is Gilead Sciences (NASDAQ:GILD).
Gilead Sciences, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for the treatment of life threatening diseases worldwide. Its products include Atripla, Truvada, Viread, Emtriva for the treatment of human immunodeficiency virus infection in adults; Hepsera, an oral formulation for the treatment of chronic hepatitis B; AmBisome, a amphotericin B liposome injection to treat invasive fungal infections; Letairis, an endothelin receptor antagonist for the treatment of pulmonary arterial hypertension; Ranexa for the treatment of chronic angina; Vistide, an antiviral medication for the treatment of cytomegalovirus retinitis in patients with AIDS; and Cayston, an inhaled antibiotic used as a treatment to enhance respiratory systems”. (Business Description from Yahoo Finance)
8 reasons Gilead looks like a good bargain at $39
(Click chart to enlarge)


  1. GILD has outperformed the overall market during the last three months of turmoil and is likely to continue to do so based on its low valuation and growing revenue (See Chart)
  2. GILD is selling at 10 times this year’s expected earnings despite growing its earnings at over a 25% annual clip over the past five years.
  3. It is selling at the very bottom of its five-year valuation based on P/S, P/E, P/B and P/CF.
  4. GILD has a five-year projected PEG of around .6, which is a 40% discount to its five-year average.
  5. Gilead has an A rated balance sheet, a super low beta (.38) and sells for around 10 times operating cash flow.
  6. GILD has a good pipeline of non-HIV drugs that

This article was written by

Bret Jensen profile picture
48.45K Followers

Bret Jensen has over 13 years as a market analyst, helping investors find big winners in the biotech sector. Bret specializes in high beta sectors with potentially large investor returns.

Bret leads the investing group The Biotech Forum, in which he and his team offer a model portfolio with their favorite 12-20 high upside biotech stocks, live chat to discuss trade ideas, and weekly research and option trades. The group also provides market commentary and a portfolio update every weekend. Learn More.

Recommended For You

About GILD Stock

SymbolLast Price% Chg
Market Cap
PE
Yield (TTM)
Rev Growth (YoY)
Prev. Close
Compare to Peers

More on GILD

Related Stocks

SymbolLast Price% Chg
GILD
--